Please assess the completion status of the following clinical trial:

Trial Title: Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Idiopathic Parkinson's disease (PD) according to United Kingdom Parkinson's Disease Society (UKPDS) Brain Bank Criteria~* Levodopa-responsive participants who demonstrate some identifiable 'on response,' established by Investigator observation~* Demonstrate severe motor fluctuations in spite of individually optimized treatment and where therapy options are indicated~Exclusion Criteria:~* Diagnosis is unclear or a suspicion of other parkinsonian syndromes exists such as secondary parkinsonism~* Undergone surgery for the treatment of PD~* Contraindications to levodopa~* Subjects with any neurological deficit that may interfere with the study assessments

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Levodopa-Carbidopa Intestinal Gel (LCIG) + Placebo Capsules (Type: EXPERIMENTAL): Participants were randomized to LCIG (levodopa, 20 mg/mL and carbidopa monohydrate, 5 mg/mL) and placebo capsules. Participants received the percutaneous endoscopic gastrostomy with jejunal extension (PEG-J) procedure for gel administration of LCIG.
- Placebo Gel + Levodopa-Carbidopa Capsules (Type: ACTIVE_COMPARATOR): Participants were randomized to placebo intestinal gel and oral levodopa-carbidopa (levodopa, 100 mg and carbidopa, 25 mg) Immediate Release (IR) capsules. Participants received the percutaneous endoscopic gastrostomy with jejunal extension (PEG-J) procedure for gel administration of placebo.

Based on this trial design, predict the completion outcome and termination type (if applicable).